# A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

> **NCT01517802** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01517802
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-28
- **Primary completion:** 2021-04-22
- **Final completion:** 2021-04-22
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517802, "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01517802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*